According to a new report published by Introspective Market Research, titled, Neuroendocrine Tumor Treatment Market by Therapy Type, Disease Indication, End-User, and Region, The Global Neuroendocrine Tumor Treatment Market Size Was Valued at USD 3.26 Billion in 2023 and is Projected to Reach USD 5.70 Billion by 2032, Growing at a CAGR of 6.4 % from 2024 to 2032. Neuroendocrine tumors (NETs) are a diverse class of cancers originating from neuroendocrine cells, which share features of nerve and hormone-secreting cells. They can arise in various organs such as the gastrointestinal tract, pancreas, lungs, and more. Treatment options include surgery, radioligand therapy, targeted therapy, somatostatin analogs, and chemotherapy. Unlike traditional broad-spectrum cancer treatments, modern therapies are advancing toward targeted, personalized approaches that improve efficacy and minimize off-target effects.
In recent years, innovations like peptide receptor radionuclide therapy (PRRT), molecular diagnostics, and novel small molecules have reshaped the landscape of NET treatment. These approaches aim to deliver therapeutic agents precisely to tumor cells expressing specific receptors, thereby reducing systemic toxicity. The NET treatment market is driven by rising incidence rates, increasing diagnosis via advanced imaging modalities, and strong pipeline activity in radiopharmaceuticals and targeted therapies.
Growing awareness among clinicians and patients, coupled with expanding reimbursement for rare disease therapeutics, is increasing adoption of advanced NET treatments. As therapeutic options broaden, patients and physicians are shifting from traditional therapies toward more effective, personalized regimens.
The Neuroendocrine Tumor Treatment Market is segmented into Therapy Type, Disease Indication, and End-User. By Therapy Type, the market is categorized into (Somatostatin Analogs, Targeted Therapy, Peptide Receptor Radionuclide Therapy, Chemotherapy, Others). By Disease Indication, the market is categorized into (Gastrointestinal NETs, Pancreatic NETs, Lung NETs, Others). By End-User, the market is categorized into (Hospitals & Clinics, Specialty Centers, Research & Diagnostic Labs).
One of the key growth drivers in the Neuroendocrine Tumor Treatment Market is the increasing adoption of peptide receptor radionuclide therapy (PRRT). PRRT enables targeted delivery of radionuclide-labeled molecules to tumor cells expressing somatostatin receptors, minimizing damage to healthy tissues. As more NET patients are identified through advanced imaging and receptor expression profiling, PRRT becomes a clinically preferred option. The success of approved agents like ^177Lu-DOTATATE has demonstrated improved progression-free survival and quality of life, encouraging further investment and acceptance of this modality.
A significant opportunity lies in the development of next-generation radiopharmaceuticals, particularly alpha-emitting radionuclide therapies. These therapies may offer higher potency at lower doses, deeper tumor penetration, and reduced radiation to surrounding healthy tissue. As research advances in linker chemistry, isotope production, and targeting ligands, pharmaceutical firms have the chance to lead the next wave of NET treatments. Given the unmet clinical needs, any successful new radioligand or targeted agent has strong potential for premium pricing and market adoption.
Neuroendocrine Tumor Treatment Market, Segmentation
The Neuroendocrine Tumor Treatment Market is segmented on the basis of Therapy Type, Disease Indication, and End-User.
Somatostatin Analogs
The Somatostatin Analogs segment is further classified into Octreotide, Lanreotide, and Pasireotide. Among these, the Octreotide sub-segment accounted for the highest market share in 2023. Octreotide remains a backbone therapy due to its long-standing clinical experience, symptom control (especially in functional NETs), and wide availability. Its established safety profile and reimbursement coverage make it a preferred first-line option in many regions, sustaining its dominance even as newer therapies emerge.
Peptide Receptor Radionuclide Therapy (PRRT)
The PRRT segment is further classified into ^177Lu-based PRRT, ^90Y-based PRRT, and Emerging Radionuclide Therapies (alpha emitters). Among these, the ^177Lu-based PRRT sub-segment accounted for the highest market share in 2023. ^177Lu-DOTATATE has demonstrated strong clinical efficacy and safety, gained regulatory approvals, and established physician confidence. It has become a standard of care in many markets, driving revenue growth and spurring further development of similar radionuclide conjugates.
Some of The Leading/Active Market Players Are-
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Ipsen Pharma (France)
- Eli Lilly and Company (USA)
- Bristol-Myers Squibb (USA)
- Camurus AB (Sweden)
- Radiomedix Inc. (USA)
- ITM Solucin GmbH (Germany)
- Clarity Pharmaceuticals (Australia)
- Takeda Pharmaceutical Company (Japan)
- other active players.
Key Industry Developments
- In October 2024, Sanofi announced its strategic investment of USD 300 million for a 16 % stake in OranoMed to support development of radiopharmaceuticals targeting neuroendocrine tumors.
The collaboration focuses on a lead-212 isotope platform designed for NETs, combining biopharma and nuclear capabilities. Sanofi aims to integrate its global distribution with OranoMed’s radiochemistry expertise. This effort accelerates development of alpha-emitter conjugates, which may offer higher therapeutic potency and lower collateral damage compared to existing beta therapies. The move underscores Big Pharma’s growing interest in radioligand markets and could reshape competitive dynamics in NET treatment. - In November 2024, Exelixis announced that its supplemental NDA for Cabometyx was accepted by the U.S. FDA for treatment of advanced pancreatic and extra-pancreatic NETs.
Cabometyx, a multikinase inhibitor, has shown efficacy in multiple tumor types. The supplemental application covers patients with previously treated NETs, expanding its label beyond current indications. If approved, it could offer a non-radioligand targeted option for NET patients, potentially improving treatment sequencing and patient access. This development may intensify competition, especially with existing therapies like everolimus and sunitinib, and raise market penetration across key geographies.
Key Findings of the Study
- Octreotide dominates somatostatin analog therapy due to clinical experience and broad use
- ^177Lu-based PRRT leads in radionuclide therapies, supported by regulatory approvals
- Radiopharmaceutical innovation, especially alpha-emitting agents, presents top growth opportunity
- NET treatment growth is supported by rising diagnosis rates and increasing clinical pipeline
- Big Pharma investments and expanded indications (e.g. Cabometyx) are reshaping market dynamics
